专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070117849A1 Alfavbeta3 and alfavbet6 integrin antagonists as antifibrotic agents 审中-公开
标题翻译： Alfavbeta3和alfavbet6整合素拮抗剂作为抗纤维化剂
公开(公告)号：US20070117849A1
公开(公告)日：2007-05-24
申请号：US10574215
申请日：2004-09-16
申请人： Simon Goodman , Detlef Schuppan , Eleonora Patsenker , Yury Popov , Michael Bauer , Matthias Wiesner , Alfred Jonczyk
发明人： Simon Goodman , Detlef Schuppan , Eleonora Patsenker , Yury Popov , Michael Bauer , Matthias Wiesner , Alfred Jonczyk
IPC分类号： A61K31/4439 , A61K31/44
CPC分类号： A61K31/00
摘要： This invention relates to inhibition of αv integrins, especially αvβ3 and αvβ6 integrins, by specific antagonists, preferably non-peptidic antagonists, related compounds and compounds with comparable specificity, that downregulate fibrogenesis by inhibiting cell migration and production of pro-fibrogenic molecules (e.g., collagens, TIMP-1) and cytokines (e.g., CTGF) by activated hepatic stellate cells/myofibroblasts, activated epithelia and endothelia. These antagonists alone or in combination with other agents can effectively prevent, mitigate or even reverse development of advanced fibrosis, such as fibrosis/cirrhosis of the liver and fibrosis of other organs, such as lungs, kidneys, intestine, pancreas, skin and arteries.
摘要翻译：本发明涉及通过特异性拮抗剂，优选非肽拮抗剂，相关化合物和具有相当特异性的化合物抑制alphav整合素，特别是alphavbeta3和alphavbeta6整联蛋白，通过抑制细胞迁移和产生促纤维化分子来下调纤维发生（例如，胶原，TIMP-1）和活化的肝星状细胞/肌成纤维细胞，活化的上皮细胞和内皮细胞因子（例如CTGF）。这些单独的或与其它药剂组合的拮抗剂可以有效地预防，减轻或甚至逆转晚期纤维化的发展，例如肝纤维化/肝硬化和其他器官如肺，肾，肠，胰腺，皮肤和动脉的纤维化。

2. 发明申请

US20120083458A1 METHODS AND COMPOSITIONS FOR DETECTING AND TREATING INFLAMMATORY DISEASE 审中-公开
标题翻译：用于检测和治疗炎症疾病的方法和组合物
公开(公告)号：US20120083458A1
公开(公告)日：2012-04-05
申请号：US13237501
申请日：2011-09-20
申请人： Detlef Schuppan , Yury Popov , Miroslaw Kornek
发明人： Detlef Schuppan , Yury Popov , Miroslaw Kornek
IPC分类号： A61K38/17 , A61P1/16 , A61P29/00 , G01N33/566
CPC分类号： G01N33/5767 , A61K35/15 , A61K38/1774 , G01N33/5094 , G01N33/6872 , G01N2333/70514 , G01N2333/70517 , G01N2800/085 , G01N2800/24 , G01N2800/7095
摘要： The invention features methods of diagnosing inflammatory disease based on the elevated presence microparticles (MP) expressing certain receptors. The invention also features methods of decreasing fibrosis in the liver by administering MP to subjects with liver fibrosis.
摘要翻译：本发明的特征在于基于表达某些受体的升高的存在微粒（MP）来诊断炎性疾病的方法。本发明还具有通过向具有肝纤维化的受试者施用MP来减少肝脏纤维化的方法。

3. 发明申请

US20050119202A1 Medicament to treat a fibrotic disease 审中-公开
标题翻译：药物治疗纤维化疾病
公开(公告)号：US20050119202A1
公开(公告)日：2005-06-02
申请号：US10493686
申请日：2002-10-25
申请人： Roland Kreutzer , Stefan Limmer , Detlef Schuppan , Matthias John , Michael Bauer
发明人： Roland Kreutzer , Stefan Limmer , Detlef Schuppan , Matthias John , Michael Bauer
IPC分类号： C12N15/09 , A61K9/127 , A61K9/50 , A61K9/51 , A61K31/7105 , A61K31/713 , A61K38/00 , A61P31/14 , C07K14/18 , C07K14/82 , C12N15/113 , C12N15/40 , C12N15/51 , C12N15/88 , A61K48/00 , C07H21/02
CPC分类号： C12N15/1131 , A61K38/00 , C12N2310/14 , C12N2310/53
摘要： The invention concerns a medicament to treat a fibrotic disease, wherein the medicament contains a double-stranded ribonucleic acid (dsRNA) that is suitable for inhibiting by RNA interference the expression of a gene that is involved in the formation of extracellular matrix.
摘要翻译：本发明涉及治疗纤维化疾病的药物，其中药物含有双链核糖核酸（dsRNA），其适用于通过RNA干扰参与细胞外基质形成的基因的表达。

4. 发明授权

US07141380B2 Assessment of liver fibrosis scoring with serum marker algorithms 有权
标题翻译：用血清标记算法评估肝纤维化评分
公开(公告)号：US07141380B2
公开(公告)日：2006-11-28
申请号：US10258689
申请日：2001-04-26
申请人： Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Mathias Gehrmann , Guido Hennig , Sylvia Unger , Elmar-Reinhold Burchardt , Michael J. Arthur , Alastair D. Burt , Massimo Pinzani , Detlef Schuppan
发明人： Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Mathias Gehrmann , Guido Hennig , Sylvia Unger , Elmar-Reinhold Burchardt , Michael J. Arthur , Alastair D. Burt , Massimo Pinzani , Detlef Schuppan
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , G01N33/6887 , G01N2333/47 , G01N2333/78 , G01N2333/8146 , G01N2333/96486 , G01N2800/085
摘要： The present invention concerns a method for diagnosing liver fibrosis wherein two or more diagnostic markers are measured and the measurements are correlated by a mathematic algorithm characterized in that the diagnostic markers are selected from the group N-terminal procollagen III propeptide (PIIINP), Collagen IV, Collagen VI, Tenascin, Laminin, Hyaluronan, MMP-2, TIMP-1 and MMP-9/TIMP-1 complex. The algorithm can be used to predict the histological score of a liver biopsy.
摘要翻译：本发明涉及一种用于诊断肝纤维化的方法，其中测量两个或更多个诊断标记物，并且通过数学算法将测量值相关联，其特征在于诊断标记物选自N-末端原胶原III前肽（PIIINP），胶原蛋白IV ，胶原VI，腱生蛋白，层粘连蛋白，透明质酸，MMP-2，TIMP-1和MMP-9 / TIMP-1复合物。该算法可用于预测肝活组织检查的组织学分数。

5. 发明申请

US20130266584A1 METHODS AND COMPOSITIONS FOR TREATING CELIAC DISEASE 审中-公开
标题翻译：治疗CELIAC疾病的方法和组合
公开(公告)号：US20130266584A1
公开(公告)日：2013-10-10
申请号：US13695349
申请日：2011-04-29
申请人： Detlef Schuppan , Yvonne Junker , Towia Libermann , Simon T. Dillon
发明人： Detlef Schuppan , Yvonne Junker , Towia Libermann , Simon T. Dillon
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/16 , C07K2317/76
摘要： The invention features the treatment of gastrointestinal disorders associated with an innate immune response tiggered by alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or alpha amylase inhibitor 0.53 (0.53). To this end, the invention features pharmaceutical compositions including neutralizing antibodies to CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53, food products containing reduced levels of CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 protein, the use of oral TLR4 inhibitors to block the effect of said alpha-amylase inhibitors, assays for identifying CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 content in food products, and assays for diagnosing subjects with a disorder related to CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 triggered innate immune responses.
摘要翻译：本发明的特征在于治疗与由α淀粉酶抑制剂CM3，α淀粉酶抑制剂0.19（0.19），CM1，CM2，CMa，CMd，CM16，CMb，CMX1 / CMX3，CMX2和/或其衍生物相关的先天免疫应答相关的胃肠道疾病 α淀粉酶抑制剂0.53（0.53）。为此，本发明的特征在于药物组合物，包括中和CM3，0.19，CM1，CM2，CMa，CMd，CM16，CMb，CMX1 / CMX3，CMX2和/或0.53的抗体，含有CM3，0.19， CM1，CM2，CMa，CMd，CM16，CMb，CMX1 / CMX3，CMX2和/或0.53蛋白，使用口服TLR4抑制剂来阻断所述α-淀粉酶抑制剂的作用，用于鉴定CM3，0.19，CM1， CM2，CMa，CMd，CM16，CMb，CMX1 / CMX3，CMX2和/或0.53含量，以及用于诊断与CM3，0.19，CM1，CM2，CMa，CMd，CM16，CMb相关的病症的受试者的测定，CMX1 / CMX3，CMX2和/或0.53触发先天免疫应答。

6. 发明授权

US07668661B2 Liver disease-related methods and systems 有权
标题翻译：肝病相关方法和系统
公开(公告)号：US07668661B2
公开(公告)日：2010-02-23
申请号：US10868437
申请日：2004-06-15
申请人： Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Sylvia Unger , Mathias Gehrmann , Guido Hennig , Elmar-Reinhold Burchardt , Michael J. Arthur , Alastair D. Burt , Massimo Pinzani , Detlef Schuppan , Robert P. Thiel , Christoph Petry , William Rosenberg
发明人： Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Sylvia Unger , Mathias Gehrmann , Guido Hennig , Elmar-Reinhold Burchardt , Michael J. Arthur , Alastair D. Burt , Massimo Pinzani , Detlef Schuppan , Robert P. Thiel , Christoph Petry , William Rosenberg
IPC分类号： G06F7/00
CPC分类号： C12Q1/6883 , G01N33/6893 , G01N2800/085 , G06F19/00 , G06F19/24 , G16H50/20 , Y02A90/26
摘要： The invention provides diagnostic methods, kits, and systems, and related computer-readable media, which use multiple blood marker values, including serum and plasma marker values, to aid in the diagnosis of the status or progress of a liver disease in a patient.The invention also provides methods and systems, and related computer-readable media, that use blood marker values, including serum and plasma marker values: (1) to screen for active ingredients useful in the treatment of a liver disease; (2) to aid in the selection of treatment regimens for patients that are predisposed to, or suffer from, liver disease; and (3) to aid in the design of clinical programs useful in monitoring the status or progress of liver disease in one or more patients.
摘要翻译：本发明提供了诊断方法，试剂盒和系统以及相关的计算机可读介质，其使用多个血液标记值，包括血清和血浆标记值，以帮助诊断患者的肝脏疾病的状态或进展。本发明还提供了使用血液标记值（包括血清和血浆标记值）的方法和系统以及相关的计算机可读介质：（1）筛选可用于治疗肝脏疾病的活性成分; （2）协助选择易患或患有肝病的患者的治疗方案; （3）协助设计有用的一个或多个病人监测肝脏病状况或进展情况的临床方案。

7. 发明申请

US20070172907A1 Liver disease-related methods and systems 有权
标题翻译：肝病相关方法和系统
公开(公告)号：US20070172907A1
公开(公告)日：2007-07-26
申请号：US10868437
申请日：2004-06-15
申请人： Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Sylvia Unger , Mathias Gehrmann , Guido Hennig , Elmar-Reinhold Burchardt , Michael Arthur , Alastair Burt , Massimo Pinzani , Detlef Schuppan , Robert Thiel , Christoph Petry , William Rosenberg
发明人： Michael Volker , Michael Becka , Werner Kroll , Andreas Knorr , Sylvia Unger , Mathias Gehrmann , Guido Hennig , Elmar-Reinhold Burchardt , Michael Arthur , Alastair Burt , Massimo Pinzani , Detlef Schuppan , Robert Thiel , Christoph Petry , William Rosenberg
IPC分类号： C12Q1/48 , G06F19/00
CPC分类号： C12Q1/6883 , G01N33/6893 , G01N2800/085 , G06F19/00 , G06F19/24 , G16H50/20 , Y02A90/26
摘要： The invention provides diagnostic methods, kits, and systems, and related computer-readable media, which use multiple blood marker values, including serum and plasma marker values, to aid in the diagnosis of the status or progress of a liver disease in a patient. The invention also provides methods and systems, and related computer-readable media, that use blood marker values, including serum and plasma marker values: (1) to screen for active ingredients useful in the treatment of a liver disease; (2) to aid in the selection of treatment regimens for patients that are predisposed to, or suffer from, liver disease; and (3) to aid in the design of clinical programs useful in monitoring the status or progress of liver disease in one or more patients.
摘要翻译：本发明提供了诊断方法，试剂盒和系统以及相关的计算机可读介质，其使用多个血液标记值，包括血清和血浆标记值，以帮助诊断患者的肝脏疾病的状态或进展。本发明还提供了使用血液标记值（包括血清和血浆标记值）的方法和系统以及相关的计算机可读介质：（1）筛选可用于治疗肝脏疾病的活性成分; （2）协助选择易患或患有肝病的患者的治疗方案; （3）协助设计有用的一个或多个病人监测肝脏病状况或进展情况的临床方案。

8. 发明授权

US07473525B2 Compositions and methods for inhibiting expression of anti-apoptotic genes 有权
标题翻译：抑制抗凋亡基因表达的组合物和方法
公开(公告)号：US07473525B2
公开(公告)日：2009-01-06
申请号：US10384260
申请日：2003-03-07
申请人： Roland Kreutzer , Stefan Limmer , Hans-Peter Vornlocher , Philipp Hadwiger , Anke Geick , Matthias Ocker , Christoph Herold , Detlef Schuppan
发明人： Roland Kreutzer , Stefan Limmer , Hans-Peter Vornlocher , Philipp Hadwiger , Anke Geick , Matthias Ocker , Christoph Herold , Detlef Schuppan
IPC分类号： C12Q1/68 , C12P19/34 , C12N5/00 , C12N5/02 , C07H21/02 , C07H21/04
CPC分类号： C12N15/113 , C12N15/1131 , C12N2310/152 , C12N2310/315 , C12N2310/3183 , C12N2310/33 , C12N2310/351 , C12N2310/3511 , C12N2310/53
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising a complementary RNA strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially identical to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell.
摘要翻译：本发明涉及用于抑制抗凋亡基因表达的双链核糖核酸（dsRNA），其包含具有长度小于25个核苷酸的核苷酸序列的互补RNA链，其至少与至少凋亡基因的一部分，如Bcl基因。本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于使用该药物组合物治疗由抗凋亡基因表达引起的疾病的方法; 以及抑制细胞中抗凋亡基因表达的方法。

9. 发明申请

US20050227916A1 Peptide stellate carrier devices for stellate cells 有权
标题翻译：用于星状细胞的肽星形载体装置
公开(公告)号：US20050227916A1
公开(公告)日：2005-10-13
申请号：US11012056
申请日：2004-12-15
申请人： Klaas Poelstra , Eleonora Beljaars , Dirk Meijer , Detlef Schuppan
发明人： Klaas Poelstra , Eleonora Beljaars , Dirk Meijer , Detlef Schuppan
IPC分类号： G01N33/566 , A61K9/00 , A61K38/12 , A61K47/42 , A61K47/48 , A61K51/08 , A61P1/00 , A61P7/00 , A61P9/10 , A61P11/00 , A61P13/00 , A61P19/02 , A61P29/00 , A61P43/00 , C07K14/71 , C07K14/715 , C07K14/765 , C07K19/00 , C12Q1/02 , G01N33/15
CPC分类号： A61K38/12 , A61K47/549 , A61K47/62 , A61K47/643 , A61K51/0491 , A61K51/081
摘要： A compound includes a carrier molecule wherein the carrier molecule is linked to a further molecule, wherein the further molecule is at least one cyclic peptide in which the cyclic peptide portion thereof contains at least one sequence encoding a cell receptor recognizing peptide (RRP) and with the proviso that the compound is not a naturally occurring receptor agonist or antagonist. Preferably, the RRP is a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is up-regulated on HSC during disease. The RFP may be chosen from among a PDGF receptor, a collagen type VI receptor, cytokine receptor(s) such as TGBβ, INFα and interleukinβ. The cyclic portion of the peptide can contain at least one amino acid sequence RGD or KPT. The compounds can be used as an active targeting ingredient for manufacturing a pharmaceutical composition for therapy, prophylaxis or diagnosis of a disease chosen from fibrotic disease, sclerotic disease, and chronic or acute inflammatory processes including glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, rheumatoid arthritis, Crohns disease, colitis ulcerosa, glomerulonephritis and sepsis, and particularly for targeting HSC. Pharmaceutical compositions contain the above-compound(s).
摘要翻译：化合物包括载体分子，其中载体分子与另一分子连接，其中另外的分子是至少一个环肽，其中环肽部分含有至少一个编码细胞受体识别肽（RRP）的序列，条件是该化合物不是天然存在的受体激动剂或拮抗剂。优选地，RRP是对肝星状细胞（HSC）特异的受体或在疾病期间在HSC上上调的受体。 RFP可以选自PDGF受体，胶原型VI受体，细胞因子受体（例如TGBbeta，INFalpha和白介素β）。肽的环状部分可以含有至少一个氨基酸序列RGD或KPT。该化合物可用作制备用于治疗，预防或诊断选自纤维化疾病，硬化性疾病和慢性或急性炎症过程（包括肾小球硬化，间质性纤维化，肺纤维化，动脉粥样硬化，类风湿病）的药物组合物的活性靶向成分关节炎，克罗恩病，溃疡性结肠炎，肾小球性肾炎和败血症，特别是靶向HSC。药物组合物含有上述化合物。

10. 发明授权

US06319726B1 Immunological method for detecting antibodies directed against tissue transglutaminase (tTG), use of tTG in diagnosis and therapy control, and an oral pharmaceutical agent containing tTG 有权
标题翻译：用于检测针对组织转谷氨酰胺酶（tTG）的抗体的免疫学方法，在诊断和治疗控制中使用tTG，以及含有tTG的口服药剂
公开(公告)号：US06319726B1
公开(公告)日：2001-11-20
申请号：US09229716
申请日：1999-01-13
申请人： Detlef Schuppan , Walburga Dieterich , Tobias Ehnis
发明人： Detlef Schuppan , Walburga Dieterich , Tobias Ehnis
IPC分类号： G01N33564
CPC分类号： C12N9/1044 , A61K38/00 , C07K14/4713 , G01N33/564 , G01N33/573
摘要： The invention relates to a method for detecting antibodies from body fluids by means of an immune reaction with tissue transglutaminase (tTG), with tTG-containing compounds, the antigenic structures, immunoreactive sequences or analogues thereof. The method may be used in the diagnosis and therapy control of diseases associated with an immune reaction against tTG, tTG-containing compounds, the antigenic structures, immunoreactive sequences or analogues thereof. Therefore, the invention is also directed to the use of tTG and the above-mentioned substances in diagnosis and therapy control, preferably in the diagnosis and therapy control of chronically inflammatory diseases or autoimmune diseases, and more preferably, in the diagnosis and therapy control of sprue or coeliac disease.
摘要翻译：本发明涉及通过与组织转谷氨酰胺酶（tTG）的免疫反应，含有tTG的化合物，抗原结构，免疫反应性序列或其类似物从体液检测抗体的方法。该方法可用于与针对tTG，含tTG的化合物，抗原结构，免疫反应性序列或其类似物的免疫反应相关的疾病的诊断和治疗控制。因此，本发明还涉及tTG和上述物质在诊断和治疗控制中的应用，优选在慢性炎性疾病或自身免疫性疾病的诊断和治疗控制中，更优选在诊断和治疗控制中浇口或乳糜泻。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式